Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BMRN
HoldPremium GrowerBioMarin Pharmaceutical Inc. · Healthcare · United States · $12.5B · Avg Vol: $138M/d
COMPANY DESCRIPTION
BioMarin Pharmaceutical Inc. is a global biotechnology company dedicated to developing and commercializing innovative therapies for rare genetic diseases, including treatments for PKU and achondroplasia. The company's competitive moat arises from its specialized focus on ultra-orphan indications, which entail high barriers to entry due to complex research and regulatory pathways, alongside deep engagement with patient communities. BioMarin is a prominent player in rare disease biopharmaceuticals, delivering critical treatments to underserved populations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.1B | 2.4B | 2.9B | 3.2B | 15.4% | 3.4B | 3.9B | 4.5B | 17.7% |
| EPS | 0.76 | 0.89 | 2.25 | 1.82 | 33.8% | 0.37 | 2.91 | — | 59.7% |
| Shares | 186.3M | 188.6M | 190.8M | 192.3M | +3.2% | 193.6M | — | — | — |
| Debt | 1.1B | 1.1B | 602.7M | 605.9M | -17.9% | 4.2B | — | — | — |
| Equity | 4.6B | 5.0B | 5.7B | 6.1B | 9.8% | — | — | — | — |
| Op CF | 175.9M | 159.3M | 572.8M | 828.0M | 67.6% | 857.1M | — | — | — |
| Inv CF | -20.0M | -111.2M | 136.5M | -414.2M | — | — | — | — | — |
| Fin CF | -18.6M | -18.7M | -526.4M | -42.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMRN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc.(you) | $12.5B | 63 | Hold |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| CAI | Caris Life Sciences, Inc. | $7.2B | 60 | Hold |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
| TGTX | TG Therapeutics, Inc. | $8.3B | 57 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 67 | Buy |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 54 | Hold |
| RPRX | Royalty Pharma plc | $35.2B | 61 | Hold |
| PTGX | Protagonist Therapeutics, Inc. | $9.3B | 44 | Hold |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.3%